The clonal nature of cancer evolution dictates that all tumor cells carry the same cancer-initiating genetic lesions. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of the tumor. Studies on different types of hematopoietic and solid tumors have shown that the contribution of some oncogenes to cancer development is mediated through the epigenetic reprogramming of the cancer-initiating target cell [1] [2] [3] [4] . Epigenetic reprogramming is therefore a new type of interaction between oncogenes and tumor cells, in which the oncogene primes for cancer development by establishing a new pathological tumor cell identity. The current challenge is to test whether epigenetic remodeling in the absence of the driver oncogene is sufficient for tumorigenesis.
Chronic myeloid leukemia (CML) is a malignancy of hematopoietic stem cells (HSCs) that harbor the Philadelphia (Ph) chromosome [5] and leads to increased abundance of myeloid cells and other non-lymphoid lineages in the blood and bone marrow. The Ph translocation creates the BCR-ABL fusion protein, with nearly all CML patients harboring a breakpoint that results in a 210-kD protein (BCR-ABLp210). This oncogene alone is capable of transforming hematopoietic progenitors and inducing CML [5] . The BCR-ABL protein is a constitutively active kinase that can be directly targeted with ABL-specific kinase inhibitors, such as Imatinib. The introduction of these agents that specifically target the cancer-initiating oncogene was a breakthrough in the clinical management of CML. However, treatment with Imatinib or other second-generation ABL kinase inhibitors is not curative and the disease returns upon cessation of the drug or the development of resistance. This is because CML stem cells are not dependent on BCR-ABL activity [6] , suggesting that there may be an oncogenic function of BCR-ABLp210 that can persist following inhibition of ABL kinase activity. In support of this notion, we have previously shown that the transient expression of BCR-ABLp210 restricted to the hematopoietic stem/progenitor cell (HSPC) compartment of mice is capable of inducing mature myeloid leukemia [7] . In addition, we have also demonstrated that the expression of other oncogenes, such as Bcl6, within the HSPC compartment can reprogram HSPCs toward malignancy by fueling epigenetic changes that can be traced from the HSPCs to the malignant cells [1] . These observations led us to hypothesize that BCR-ABLp210 may function, in part, via epigenetic mechanisms that prime the tumor stem cell for malignant myeloid differentiation.
In order to investigate epigenetic reprogramming by the BCR-ABLp210 oncogene, we performed reducedrepresentation bisulfite sequencing to interrogate the DNA methylation landscape in HSPCs (Sca1+Lin−) from wildtype and Sca1-BCR-ABLp210 transgenic mice. The methods for all experiments are described in detail in supplementary information. This revealed a broad and significant loss of methylation at CpG islands that have a lowto-moderate level of methylation in wild-type HSPCs (Fig. 1a , Table S1 ). Importantly, this hypomethylation phenotype was conserved in mature myeloid cells from Sca1-BCR-ABLp210 mice, despite the absence of the BCR-ABLp210 oncogene in these cells ( Fig. 1a, b , Table S2 ). This shows that transient HSPC-restricted expression of the BCR-ABLp210 oncogene is capable of inducing significant
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Prior studies have shown that DNA methyltransferase (DNMT) genes, including DNMT1, are aberrantly overexpressed in myeloid leukemias [8] . In line with this, gene (top) or old (bottom) wild-type control mice compared to those from young Sca1-Dnmt1 mice. A clear loss of methylation can be observed in regions with a normally low-to-moderate level of methylation (0.1-0.2) in control mice. Bar graphs summarize the percentage of major hematological populations, interrogated by flow cytometry of bone marrow and peripheral blood of young (top) and old (bottom) wild-type and Sca1-Dnmt1 mice. No significant differences were observed in the bone marrow at either time point. A significantly increase in the percentage of myeloid cells was observed in the peripheral blood of young disease-free Sca1-Dnmt1 mice compared to their wild-type counterparts (T test P value < 0.001), but this was not observed in older mice. b Kaplan-Meier plot shows a significant reduction in survival of Sca1-Dnmt1 mice (blue) compared to their wild-type counterparts (gray). Pie graphs summarize the necropsy results from Sca1-Dnmt1 mice, with 75% of animals bearing tumors that were primarily of hematopoietic origin. c An illustrative example of flow cytometry of diseased Sca1-Dnmt1 mice compared to agematched controls shows the expansion of Gr1 + Mac1 + myeloid cells in the blood and bone marrow, as well as the appearance of an abnormal Gr1 low Mac1 + population in the bone marrow expression profiling (GEP) data from HSPCs of Sca1-BCR-ABLp210 mice compared to those from wild-type mice [7] showed upregulation of Dntm1 and downregulation of Dnmt3b expression, with no change in Dnmt3a expression ( Fig. 1c ). Higher expression of DNMT1 was also observed in GEP data from human CML stem cells compared to normal HSCs [9] (T test P value = 0.003; Fig. 1c ). The expression of DNMT3A was also significantly higher (T test P value = 0.012). Furthermore, GEP data from untreated and Imatinib-treated bone marrow cells of CML patients [10] showed that inhibition of BCR-ABL significantly reduces DNMT1 expression (T test P value = 0.0004; Fig. 1c ). Together these data show that BCR-ABLp210 expression is associated with overexpression of DNMT1 in both murine and human HSCs and that its expression may be linked to the activity of this oncogene.
The deregulation of DNA methylation by somatic mutations is one of the hallmarks of acute myeloid leukemia. Mutations of IDH1, IDH2, or TET2, function in the same pathway and inhibit the active and passive recycling of 5-methylcytosine to cytosine thereby inducing global hypermethylation. In contrast, mutations of the de novo methyltransferase, DNMT3A, function as dominant negative to inhibit the formation of DNMT3A homotetramers that efficiently methylate cytosine and leads to global hypomethylation. The DNMT3A protein performs its role as a de novo methyltransferase following its recruitment by other transcriptionally repressive complexes such as the polycomb repressor 2 (PRC2) complex [11] . DNMT1, DNMT3A, and DNTM3B have each been shown to interact with a similar region of the catalytic subunit of PRC2, EZH2 [11] . It is therefore plausible that overexpression of DNMT1 may sterically hinder the association between EZH2 and DNMT3A. The loss of only a single allele of Dnmt3a is sufficient to promote myeloid leukemia in mice, despite causing only modest changes in DNA methylation [12] , demonstrating that slight perturbations in Dnmt function are sufficient for leukemogenesis. Human CML also shows disordered DNA methylation [13] , but the mechanism for this has not been defined. Deregulation of this axis is therefore clearly important for myeloid malignancies. But there is still not a clear understanding of specific genes or pathways that contribute to myeloid transformation as a result of perturbations in DNA methylation. Our observations therefore led us to investigate whether Dnmt1 overexpression was mechanistically linked with perturbed DNA methylation and myeloid leukemogenesis.
Transient expression of BCR-ABLp210 in HSPCs was sufficient to promote myeloid leukemia, and Imatinib treatment leads to downregulation of Dnmt1 but does not eradicate the disease. We therefore hypothesized that transient expression of Dnmt1 would also be sufficient for stem cell reprogramming, and we modeled this by expressing Dnmt1 under control of the endogenous Sca1 promoter for HSPC-restricted expression (Figs. S1-2). Notably, the expression of Dnmt1 resulted in DNA hypomethylation in HSPCs similar to that observed in Sca1-BCR-ABLp210 mice, with the most notable changes at loci with normally low/moderate levels of methylation ( Fig. 2a , Table S3 ). No significant alterations were observed in the frequencies of major hematologic subsets in the bone marrow of young Sca1-Dnmt1 mice (3-7 months), but there was a significant expansion of myeloid cells in the peripheral blood compared to wild-type mice ( Fig. 2a ). Although the DNA hypomethylation phenotype persisted in the HSPCs of older mice (16-24 months, Fig. 2a , Table S4 ), there was no significant difference in myeloid cells in either the bone marrow or the peripheral blood at this stage. The HSPCrestricted expression of Dnmt1 is therefore capable of phenocopying the pattern of lasting DNA hypomethylation that was observed in BCR-ABLp210 mice.
Aging Sca1-Dnmt1 mice had a shorter lifespan than wild-type mice due to the development of cancer, the majority of which were myeloid malignancies ( Fig. 2b) . The Sca1-Dnmt1 mice that developed myeloid malignancies showed marked expansion of Mac1 + Gr1 + granulocytes in the blood and bone marrow ( Fig. 2c and S3 ), as well as the presence of an abnormal myeloid population (Mac1 + Gr1 low ) in the bone marrow ( Fig. 2c ). This was also associated with a loss of normal architecture in the spleen (Fig. S4) , with tumor-bearing Sca1-Dnmt1 mice showing atrophic white pulp and hyperplasic red pulp infiltrated by myeloid cells. In the liver, tumor infiltration was accompanied by deposition of an eosinophilic hyaline substance ( Fig. S4) . A prior study showed that the expression of a hypomorphic Dnmt1 allele induced global DNA hypomethylation and led to tumors in mice [14] , potentially via the promotion of chromosomal instability resulting from the reactivation of endogenous retroviral elements [15] . We did not observe the expression of the Cdkn2a (p19 Arf ) gene in bone marrow cells from Sca1-Dnmt1 mice, indicating the absence of oncogenic stress resulting from chromosome instability (data not shown). Together, these data show that HSPC-restricted expression of Dnmt1 is sufficient to phenocopy the DNA hypomethylation phenotype induced by BCR-ABLp210 expression in the same compartment and to promote the development of myeloid malignancies. The deregulation of DNA methylation alone is therefore sufficient to prime HSPCs for the development of myeloid leukemia.
In conclusion, here we have characterized epigenetic reprogramming linked to HSPC-restricted expression of BCR-ABLp210, which persists in myeloid cells despite the absence of the oncogene. We identified upregulation of Dnmt1 as a consequence of BCR-ABLp210, and we show that HSPC-restricted expression of Dnmt1 in transgenic mice is sufficient to phenocopy the BCR-ABLp210-associated DNA methylation changes and induce myeloid malignancies. This provides, to our knowledge, the first experimental evidence that epigenetic tumor stem cell reprogramming by itself is sufficient to drive cancer development and establish the tumor cell identity. These observations provide important mechanistic insight into the epigenetic reprogramming of HSC by the BCR-ABLp210 oncogene and the etiology of CML. Systemic light chain (LC) amyloidosis (AL) is a protein misfolding disease in which a monoclonal immunoglobulin LC self-aggregates to form insoluble amyloid fibrils, which deposit in different organs and impairs the physiology of organs [1] . Researchers postulated that glycosylation also has a pathogenic effect on LCs and glycosylated LCs could be more prone to be amyloidogenic [2] . Pathogenic glycosylation of proteins has been implicated in various hematological malignancies, often with prognostic implications [3] . However, in comparison with other diseases, glycosylation of LCs has been relatively underinvestigated in AL. This is largely due to the lack of a high-throughput procedure to facilitate rapid analysis of LC glycosylation. Previous studies using immuno-enrichment-based matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), termed MASS-FIX, demonstrated that M-protein mass distributions from AL patients often had an additional "polytypic-like" pattern along with the diagnostic monoclonal LC [4] . Further studies using high-resolution liquid chromatography-based MS (LC-MS) suggested that posttranslational modifications such as glycosylation on LCs could produce this "polytypiclike" pattern in AL patients [5] . Using MS approaches, we provide the most comprehensive mapping of LC glycosylation in AL reported to date.
We obtained serum or plasma samples from total 311 patients and arranged them into two cohorts. The first cohort had 157 AL previously untreated patients who had their amyloid protein sequenced by LC-MS/MS [1] . The second cohort included 154 patients who had previously untreated AL (n = 32) or another diagnosis such as multiple myeloma (n = 54), Waldenstrom macroglobulinemia (n = 8), monoclonal gammopathy of undetermined significance (n = 57), and other plasma cell disorder (PCD) [4] ( Table 1) .
The immuno-enrichment was performed as previously described by adding 10 μL aliquot of serum to 20 μL agarose beads coupled with one of the single-domain antibodies specific for heavy chain (HC) of IgM, IgA, and IgG, and LC of κ or λ constant domains (Thermo Fischer Scientific), washed, reduced, spotted on MALDI target plate (Bruker), and analyzed separately on MALDI-TOF-MS (Microflex LT, Bruker) [4, 6] . The spectra from each five immuno-enrichment of each sample were overlaid and LC m/z distribution was visually inspected for the presence of peaks in [M + 1 H] 1+ and [M + 2 H] 2+ using Flex Analysis software (Bruker), and categorized patient's monoclonal LC as either "suspected-glycosylation or "no glycosylation" based on observed peak patterns.
Deglycosylation was executed to confirm suspectedglycosylation in monoclonal LC. Briefly, 10 µl of serum of suspected-glycosylation sample was mixed with 20 µl of either κor λ-specific beads, and incubated for 45 min at room temperature. After washing with phosphate-buffered saline and water, the mixture were denatured and reduced with 100 µl of 2% SDS and 10 mM Tris (2-carboxyethyl) phosphine at 56°C for 30 min with shaking. SDS was removed using DRS spin column (Thermo Fischer Scientific). The reduced LCs was treated with 1 µl of PNGase F (New England Biolab, Inc.) at 37°C for 3 h with shaking. Reactions were stopped by adding 20 µl of 0.1% trifluoroacetic acid and analyzed on MALDI-TOF-MS.
The same suspected-glycosylation-LC samples were further analyzed on high-resolution LC-MS consisting of Orbitrap Elite (Thermo Fisher Scientific) coupled to an Ultimate 3000 HPLC system (Thermo Fisher Scientific) using ProSwift RP-4H capillary monolithic column (Thermo Fisher Scientific). The spectra were acquired in positive mode between 500 and 3000 m/z in Orbitrap, and analyzed using Xcalibur Qual Browser software (Thermo Fisher Scientific). The difference in mass of suspectedglycosylation-LC before and after PNGase F treatment was determined, and matched with mass of immunoglobulin Nglycans. All experiments were repeated in three replicates.
The differences between patient groups were calculated using Fisher's exact test (JMP 13 SAS, Carey, NC). The odds ratio for suspected-glycosylated-LC patient being AL was 12.68 for κ and 2.20 for λ ( Table 1 ). This study was approved by the Mayo Clinic Institutional Review Board.
The mass spectra for all patients were classified into two mutually exclusive categories: suspected glycosylation (n = 38) and no glycosylation (n = 273) ( Supplementary Figure 1) . Suspected glycosylation LC presented as a broad peak in MS spectrum that was higher in mass than expected for LCs. Thirty-three percent of AL-κ patients had suspectedglycosylation pattern, compared with 10.2% of AL-λ patients. The rate of suspected-glycosylation LC among non-AL, κ, and λ patients was 3.7% and 4.9%, respectively ( Table 1) . Of the 38 patients with suspected-glycosylated LCs, 16 were LC-only patients and 22 patients had intact Mproteins along with their free LCs. Among the λ patients (Table 1) , the λ free LC was higher in the suspectedglycosylated patients than the non-glycosylated patients, which could be a function of the assay's inability to detect glycosylation in a very small clone in a polyclonal background with the current immuno-enrichment methodology. Once LC beads become available as part of the pre-analytics and/or more urine samples are tested, there will likely be a greater ability to detect these patterns in smaller clones.
To confirm LC glycosylation, the subset of 21 κ (18 AL and 3 non-AL) and 9 λ (7 AL and 2 non-AL) suspectedglycosylation samples were analyzed using PNGase F on MALDI-TOF-MS. The LC spectra of all 30 samples shifted to a narrower and lower molecular mass after PNGase F as compared with native LC peak, in both [M + 2 H] 2+ and [M + 1 H] 1+ charged states, indicating N-glycosylation ( Fig. 1a ).
To further verify the MASS-FIX pattern represented Nglycosylation, 19 (13 κ and 6 λ) suspected-glycosylation-LC samples were studied by LC-MS using PNGase F; all samples demonstrated a shift toward lower molecular weight after PNGase F treatment, affirming that the broad peak patterns observed by MASS-FIX were a signature for glycosylated LCs. The difference in mass before and after PNGase F was matched with molecular weights of known N-glycans ( Fig. 1b ). Bi-antennary sialated N-glycan forms G2FNSA2 and G2FSA2 were observed in most cases, whereas others had fragments of these glycan groups (Supplementary Table 1 ).
As 158 patients had their LC gene sequence by tissue mass spectrometry [1] , associations between immunoglobulin LC usage and the presence of glycosylation were sought. As shown in Fig. 1c , 41% of AL whose amyloid protein was of the KV1 gene family had glycosylated circulating LC. The κ-LCs derived from KV1-33 and KV1-39 were most represented (Fig. 1d ). The λ gene family most represented was LV3, with LV3-21 having the highest likelihood of being glycosylated.
Until now, a limited number of patients had been studied to investigate N-glycosylation of LCs in AL [7, 8] . In 2000, Stevens [9] summarized the glycosylation literature. Only 9 of 22 λ-LC proteins exhibiting potential glycosylation sites were from AL patients. In contrast, 18 of 22 potentially glycosylated KV1, LCs were from AL patients despite the fact that germline KV1 genes do not encode for N-linked glycosylation motif (N-x-S/T) [9] . It is noteworthy that we have observed that 8.5% (81/948) of KV1 mRNA sequences of various PCDs including AL derived from a LC sequence database had an N-glycosylation motif [10] . These results suggest somatic hypermutation affinity maturation of κ-LCs generates N-glycosylation sites (N-x-S/T). N-glycosylation has been reported in κ-LCs from urine in two AL patients, who had consensus glycosylation sequence (N-x-S/ T) in germline using chromatography and MALDI-TOF-MS [11] , but chromatography is analytically complex, cumbersome, and time consuming, making it unsuitable for routine clinical use. In contrast, our novel MASS-FIX method easily and rapidly characterizes LC glycosylation.
Several studies have described carbohydrate moieties in their LC of patients with PCDs; [12] it was recognized that 4% (3/71) of Bence Jones proteins from myeloma patients' urine and 11% (2/18) of LCs from multiple myeloma serum had carbohydrate moieties attached [13] . Prior studies identified sialic acid, N-acetyl-glucsosamine, N-acetyl-galactosamine, and other "neutral sugars" attached to LCs [13] . Approximately 15% of immunoglobulin LCs in circulation have been shown to have oligosaccharides [13] . In the present study, the most common N-glycans were found to be G2FNSA2 and G2FSA2 as biantennary and sialated, which supports the previous study that LCs are highly sialylated [14, 15] . Despite the disparity of frequency of N-glycosylation for κ and λ-LCs, the composition of N-glycans did not appear to be different. . After PNGase F treatment, monoclonal κ light chain is resolved to a single peak of 23,441 Da (lower panel). The difference in molecular weight of peak before and after PNGase F was matched with molecular weight of different glycans as G2FNSA2, G2NSA2, G2SA2, and G2NSA mentioned in Supplementary Table 1 . c Immunoglobulin LC gene usage based on the presence or absence of LC glycosylation. Gene family and gene usage was determined by bottom-up sequencing of amyloid from tissue biopsy [11] . By gene family: KV1 and KV4 gene families had highest rates of glycosylation. d A closer look at the KV1 gene family: 25% of KV1-33 and 41% of KV1-39 patients' monoclonal serum immunoglobulin light chains were glycosylated In summary, we identified N-glycosylation in the serum LCs of one-third of κ-AL and 10% of λ-AL patients. The novelty of our work is the application of a quick, inexpensive, high-throughput method to identify LC N-glycosylation, i.e., MASS-FIX. Although this finding will apply to only 11% of AL cases (one-third of AL cases are κ and one-third of κ-AL are glycosylated), we anticipate that over the next decade, MASS-FIX will replace immunofixation as a screen for monoclonal proteins, providing both information on isotype for all patients and AL risk in a subset. Moreover, with better immune-enrichment, the twofold higher rate of glycosylation observed in λ-AL cases over other PCDs may become significant, further increasing the value of this method to prompt clinicians to have a higher suspicion for AL in an even higher proportion of patients. by the Predolin Foundation, the JABBS Foundation, a generous donation in the memory of Joey Bartzis, and by NIH grant CA125614.
Author contributions: SK performed the experiments and drafted the manuscript. SK, AD, DLM, and SD designed, analyzed, interpreted the data, and edited the manuscript. BM performed the LC-MS experiments. PM had performed the experiments on the 154 patients from a prior report. TK and SD had performed the analyses of tissue amyloid as per a prior publication. Other authors contributed intellectual content and review of this manuscript. The trial was stopped prematurely after one year due to a significant difference in overall survival (OS), favoring the low-dose DEX arm (96 vs. 87%, p < 0.001). This difference was caused by an increased rate in early mortality and toxicities grade ≥ 3 (mainly infections, deep vein thrombosis, and fatigue) within the first four months in the high-dose DEX arm (early deaths: 12 vs. 1, p = 0.003; grade ≥ 3 toxicity: 52 vs. 35%, p < 0.001) [1] . To date, no comparison of high vs. low DEX doses has been performed in transplant-eligible NDMM receiving the proteasome inhibitor (PI) bortezomib (BTZ), which is widely applied during induction therapy (IT) prior to stem cell collection and high-dose therapy (HDT).
Compliance with ethical standards
Therefore, our present analysis retrospectively compared IT regimens from two subsequently conducted multicenter phase III trials applying BTZ (1.3 mg/m 2 on days 1, 4, 8, 11) and doxorubicine (DOXO, 9 mg/m 2 on days 1-4) with either high-dose DEX (hd-PAD, 40 mg on days 1-4, [9] [10] [11] [12] [17] [18] [19] [20] 16) as applied in the subsequent GMMG MM5 trial (07/2010-11/2013, n = 111). Primary endpoints for these trials have been published previously [2, 3] . The trials were conducted in accordance with the European Clinical Trial Directive, the Declaration of Helsinki and local ethics committees. The maximum age for inclusion was different between the trials (HD4: 65 years vs. MM5: 70 years). Therefore, we included only patients up to 65 years in the MM5 ld-PAD group. BTZ was administered intravenously (IV) in the HD4 trial. In the MM5 trial, the route of administration of BTZ was changed from IV to subcutaneous (SC) in 02/2012. Since SC BTZ resulted in lower overall adverse events (AE), peripheral neuropathy (PN), gastrointestinal and metabolic/ nutritional AE compared to IV BTZ [4] , only patients receiving IV BTZ were included in the ld-PAD group (MM5) for the current analysis.
The IT period was defined from first IT dose until last IT dose plus 30 days or start of stem cell mobilization. The DEX dose was reduced in the MM5 trial because the rates of severe infections during IT (defined as ≥ grade 3 according to the National Cancer Institute Common Terminology Criteria for Adverse Events, CTCAE) were persistently high with the use of hd-PAD compared to vincristine / DOXO / DEX (VAD; VAD 27.6% vs. hd-PAD 27.1%) and infections were a major cause of death during IT in the HD4 trial, with 7 of 12 deaths (58%) being primarily infection-related. Antibiotic prophylaxis was strongly recommended in the HD4 trial from 02/2007 (n/N = 47/66 received antibiotic prophylaxis) onwards and throughout the whole MM5 trial (n/N = 104/111 received antibiotic prophylaxis). Recommended antibiotic prophylaxis consisted of either ciprofloxacin (500 mg, twice daily) or trimethoprim-sulfamethoxazole (800/160 mg, twice daily) during the whole course of IT. Baseline and trial characteristics for the hd-PAD (as applied in the HD4 trial) and ld-PAD (as applied in the MM5 trial) group are displayed in Supplemental Table 1 .
The mean applied doses of DEX in the hd-PAD and ld-PAD group were 456.6 vs. 230.5 mg per cycle (p < 0.001), respectively. The full DEX dose for three cycles of IT was applied in 63.5 vs. 63.1% (p = 0.82) of patients in the hd-PAD and ld-PAD group, respectively. DEX was reduced in 11.5 vs. 8.1% (p = 0.43) and interrupted in 5.7 vs. 1.8% (p = 0.14) of patients in the hd-PAD and ld-PAD group, respectively. The mean applied doses of BTZ and DOXO during IT were similar between the hd-PAD vs. ld-PAD groups, respectively (BTZ: 14.3 vs. 14.3 mg/m 2 , p = 0.95 and DOXO: 102.4 vs. 102.2 mg/m 2 , p = 0.73).
The incidence of grade ≥3 adverse events (AE), serious AE (SAE), severe infections, thromboembolic events (TEE), peripheral neuropathy (PN), gastrointestinal toxicity and deaths during IT are shown in Table 1 . The incidence of severe infections (grade ≥3) and any SAE during IT were significantly lower in the ld-PAD compared to the hd-PAD group (9.9 vs. 27.1%, p < 0.001 and 28.8 vs. 41.1%, p = 0.04). Accordingly, the incidence of any AE (grade ≥ 3) and infection-related SAE were lower in the ld-PAD vs. hd-PAD arms (49.5 vs. 60.4%, p = 0.07 and 11.7 vs. 20.3%, p = 0.06). Hematological toxicities were comparable between the ld-and hd-PAD groups ( Table 1) . Since antibiotic prophylaxis might influence the rate of infections, we compared patients who received antibiotic prophylaxis between the two PAD groups. However, the incidence of severe infections during IT remained significantly different among patients receiving antibiotic prophylaxis favoring the ld-PAD group (ld-PAD: 10.6% vs. hd-PAD: 27.7%, p = 0.01).
Higher DEX doses can increase response to therapy [1] . Comparison of the hd-and ld-PAD group revealed no significant differences in response and progressive disease rates, also in the subgroup with adverse cytogenetics (defined as either deletion17p13 and/or translocation t(4;14) and/or gain1q21 [≥3 copies] [5] ; Table 2 ).
The proportion of patients completing three IT cycles and proceeding to subsequent stem cell mobilization therapy were similar between the ld-and hd-PAD group as was mortality during IT (ld-PAD 3/111 [2.7%] deaths vs. hd-PAD 4/192 [2.1%] deaths, p = 0.71).
In line with the results from Rajkumar and colleagues [1] , we found a lower number of severe infections, overall adverse events and SAE during early therapy. Expectedly, this did not translate into a lower mortality during IT in the ld-PAD group, because a short and fixed number of three IT cycles was applied. Further, the treated cohort was younger in our trials compared to the study from Rajkumar et al. [1] . Regarding age (maximum 65 years) and the route of administration of BTZ (IV only) the two PAD groups in our present analysis were comparable, excluding a bias from these factors. A comparison of hd-and ld-PAD beyond IT, e.g., regarding OS, remains difficult since DEX was only applied during IT and not continuously as with LEN. Further, in the HD4 and MM5 trials, different HDT policies (tandem HDT irrespective of response [HD4] vs. tandem HDT for patients not receiving a near CR (nCR) after first HDT [MM5]) and maintenance therapies (BTZ in the HD4 vs. LEN in the MM5 trial) were applied. Response rates were not affected by the reduced DEX dose.
Severe infections remain a major issue during the initial treatment of MM. A randomized study of continuous antibiotic prophylaxis (n = 212) with either ciprofloxacin vs. trimethoprim-sulfamethoxazole vs. observation during the first 2 months of treatment did neither demonstrate a reduction of severe bacterial infections (12.5% vs. 6.8% vs. 15.9%, p = 0.22) nor mortality [6] . The TEAMM (Tackling Early Morbidity and Mortality in Myeloma) trial, a large randomized, placebo-controlled study (n = 977), compared the prophylactic use of levofloxacin versus placebo during the first 12 weeks of treatment in NDMM [7] . The combined primary endpoint, febrile episodes or death from any cause, was significantly improved with the use of levofloxacin (hazard ratio 1.52, p = 0.002) with no differences in overall survival after one year (p = 0.94). The thrice weekly application of trimethoprim-sulfamethoxazole for pneumocystis prophylaxis was additive with the effects of levofloxacin and the carriage of nosocomial pathogens was not increased by the prophylactic use of levofloxacin. In comparison to the TEAMM trial, our study recommended ciprofloxacin or trimethoprim-sulfamethoxazole twice daily as antibiotic prophylaxis and was neither randomized to compare antibiotic prophylaxis nor placebo-controlled. Patients included in the TEAMM trial had a higher median age of 67 years and only 54% were considered transplant-eligible compared to our study, which included only transplant-eligible patients with a median age of 57 years. Taken together, our results on antibiotic prophylaxis have to be interpreted with caution, whereas the data from the TEAMM trial support the prophylactic use of levofloxacin and trimethoprim-sulfamethoxazole in NDMM.
Taken together, our study demonstrates lower toxicity and maintained efficacy with the use of ld-PAD compared to hd-PAD as IT for transplant-eligible NDMM. Studies applying modern IT regimens including BTZ plus LEN, thalidomide or cyclophosphamide and DEX are needed to confirm these results. This study supports the hypothesis that the application of reduced DEX doses during IT yields The mitochondrial cell death pathway is initiated by proapoptotic BH3-only effector proteins, such as BIM, BID, NOXA, and PUMA, which activate the multidomain cell death proteins, BAX and BAK [1] . The survival of tumor cells, as well as normal cells, is promoted by anti-apoptotic BCL-2-family members, including BCL-2, BCL-X L , and MCL1, which bind and sequester BH3-only proteins, thus preventing them from activating BAX and BAK [1] . Cancer cells tend to rely more heavily on anti-apoptotic BCL-2 family proteins because of replicative and other stresses that accompany malignant transformation, and thus are "primed" to undergo apoptosis more readily than normal cells [1] . Small molecules have been developed that mimic the BH3 domain and block binding of endogenous BH3 proteins to a groove on the surface of one or more of the pro-survival proteins. Promising examples are navitoclax/ ABT-263, targeting BCL-2, BCL-X L , and BCL-W, and more recently venetoclax/ABT-199 targeting BCL-2 alone [2] . The most successful of these drugs is the BCL-2 inhibitor venetoclax, which is approved for the treatment of chronic lymphocytic leukemia (CLL) [2, 3] and has shown considerable activity in therapy for other cancers, such as acute myeloid leukemia (AML) [4] . Venetoclax is better tolerated than navitoclax, because it does not bind to BCL-X L , which is required for the survival of normal platelets [3] .
Although T-cell acute lymphoblastic leukemia (T-ALL) is similar in many ways to CLL and AML, it has not responded well to venetoclax or navitoclax BH3 mimetics, presumably because it expresses active pro-survival proteins other than BCL-2, BCL-X L , and BCL-W. We and others have previously tested venetoclax and navitoclax against a number of human T-ALL cell lines, observing submicromolar activity only in the Loucy cell line, which is thought to represent early thymocyte precursor (or ETP) ALL, a T-ALL subtype with a particularly poor prognosis [5] [6] [7] . Venetoclax has been tested in multiple clinical trials (https://clinicaltrials.gov/) and is approved for the treatment of CLL [2, 3] , but it has just begun to be tested in patients with T-ALL. This led us to postulate that T-ALL cells might depend upon MCL1, a labile pro-survival member of the BCL-2 family that has been shown to mediate resistance to BCL-2 inhibitors [8, 9] . Thus, inhibitors of MCL1 appear especially attractive for combination with BCL-2 inhibitors for the treatment of T-ALL and other cancers. A new BH3 mimetic, S63845, was recently found to selectively target MCL1, and S63845 has been tested in many preclinical models of human cancer [10] , including breast cancer [11] , but not in T-ALL. Clinical data for the activity of MCL1 inhibitors, including S63845, have as yet not been reported. Thus, we sought to test the hypothesis that S63845 will actively induce apoptosis in T-ALL cells when given as a single agent, and also that it might produce synergistic effects when used in combination with the BCL-2 inhibitor venetoclax.
Thus, we first tested a panel of 11 T-ALL cell lines for their sensitivity to S63845. Each line was sensitive to S63845 treatment as shown by 50% growth inhibitory These authors contributed equally: Zhaodong Li and Shuning He (IC 50 ) values in a submicromolar range (Fig. 1a) . The values for two of the most sensitive cell lines, MOLT-3 and RPMI-8402, were as low as 10 nM. These results indicate that MCL1 plays an important role in maintaining the survival of most T-ALL cells. Consistent with previous studies in AML, chronic myeloid leukemia, and diffuse large B-cell lymphoma cell lines [10] , we did not observe correlation between MCL1 protein levels and sensitivity to S63845 in these T-ALL cell lines. Similarly, BCL-2 and BCL-X L levels did not predict response to S63845 treatment ( Supplementary Figure 1) . We also tested the activity of A-1210477, another MCL1-specific inhibitor [12] , against these T-ALL cell lines in comparison with the activity of S63845. The IC 50 values for A-1210477 were in the high micromolar range ( Supplementary Figure 2) , indicating that S63845 is much more potent in a cellular context, even though both drugs exhibit high affinity and specificity for the MCL1 protein in vitro [10, 12] .
Next, we tested whether the effects of S63845 were mediated through the activation of apoptosis. Using four relatively sensitive T-ALL cell lines based on IC 50 values-HPB-ALL, Loucy, MOLT-3, and RPMI-8402-we demonstrated the induction of significant apoptosis by annexin V/propidium iodide (PI) staining after 24 h of treatment with S63845 ( Supplementary Figure 3a, b) . Western blot analysis after 24 h of treatment with 200 nM S63845 showed appreciable PARP cleavage, a reliable marker of cell apoptosis, in each of these four cell lines ( Supplementary Figure 3c ). Taken together, these data demonstrate that a representative panel of T-ALL cell lines are sensitive to the S63845 inhibitor and thus depend on MCL1 for cell survival.
The anti-apoptotic BCL-2 family proteins BCL-2, BCL-X L , and MCL1 can each bind and sequester BH3-only pro-apoptotic proteins, such as BIM, BID, and PUMA [2, 13] , raising the possibility that two very specific inhibitors such as venetoclax (BCL-2) and S63845 (MCL1) might act synergistically to kill T-ALL cells. To test this hypothesis, we treated T-ALL cells with serial dilutions of S63845 and venetoclax, either alone or in combination. Our results, shown in Fig. 1b and Supplementary Figure 4 for KOPT-K1 and PF-382 cells, indicate much greater decreased cell viability in cells treated with both agents in combination. This result reflects the induction of apoptosis as shown by annexin V and PI staining ( Fig. 1c and Supplementary Figure 5 ). To determine whether the combined Fig. 1 The MCL1-specific inhibitor S63845 actively kills human T-ALL cells and strongly synergizes with venetoclax. a Eleven human T-ALL cell lines were treated with serial dilutions of S63845. Cell viability was determined by Cell-Titer Glo assay after 72 h of treatment. b KOPT-K1 cells were treated with serial dilutions of venetoclax or S63845, alone or in combination. Cell viability was determined using Cell-Titer Glo after 48 h of treatment. c KOPT-K1 cells were treated with 500 nM venetoclax and 50 nM S63845, alone or in combination. Apoptosis was measured by annexin V/PI staining after 24 h of treatment. d Combination treatment of venetoclax and S63845 depicted as normalized isobolograms shows strong synergy between the two BH3 mimetics in KOPT-K1 cells. Calcusyn software was used to analyze combination data to produce the isobolograms normalized to the IC 50 of each drug. The cells were treated with the following serial dilutions of combination doses: venetoclax, from 5.5 nM to 4000 nM; and S63845, from 1.4 nM to 1000 nM for 48 h. A combination index (CI) of 1 indicates an additive effect, CI < 1 a synergistic effect and CI > 1 antagonism effects of S63845 and venetoclax are additive or synergistic, we performed isobologram analysis after 48 h of combination treatment with serial dilutions of S63845 and venetoclax. These agents proved highly synergistic against each of the four T-ALL cell lines tested-KOPT-K1, PF-382, Jurkat, and CCRF-CEM ( Fig. 1d and Supplementary Figure 6) , with an average combination index (CI) of < 0.25 (a CI of 1 reflects an additive effect, CI < 1 a synergistic effect and CI > 1 indicates antagonism). As shown in Supplementary  Figure 7a , protein levels of MCL1 were increased after venetoclax treatment, but venetoclax treatment had little effect on the expression of both BCL-2 and BCL-X L . Based on the work of Choudhary et al. [9] , increased MCL1 levels are expected and may be due to increased MCL1 protein stability after treatment with venetoclax. As observed previously [10] , treatment of S63845 also caused upregulation of MCL1 levels with little effect on expression levels of BCL-2 and BCL-X L (Supplementary Figure 7b) . Thus, the compensatory upregulation of MCL1 suggests a molecular basis for both the lack of response of most T-ALL lines to venetoclax treatment [5] and for the synergy between S63845 and venetoclax in these T-ALL cell lines.
To assess the potential toxicity of this combination in normal cells in vivo, a critical concern when testing such agents for possible use in patients, we turned to our zebrafish model of T-ALL [14] . We first added each of the two compounds at graded doses as single agents to the fish water of normal 3-day-old zebrafish embryos. After Zebrafish embryos transplanted with T-ALL cells were treated as indicated for 4 days, with drug refreshment every 2 days, and then the drugs were removed before feeding was initiated and the developing zebrafish larva were observed for 10 more days (n = 12 for CTR, S63845, and venetoclax treatment groups; n = 13 for combined treatment group) 4 days of treatment, we determined that the maximum tolerable dose of both S63845 and venetoclax was 10 μM. Developmental defects of multiple organs including the liver, swim bladder, and gastrointestinal tract were observed in embryos treated with 15 μM S63845 (Supplementary Figure 8 ). However, we found no evidence of toxicity in embryos treated with 10 μM S63845 alone or in combination with 10 μM venetoclax, indicating that the combination is well tolerated at these dosages by healthy tissues in vivo.
To determine the anti-T-ALL activity of S63845 and venetoclax, we harvested green fluorescent protein (GFP)labeled zebrafish T-ALL cells from 3-month-old Tg(rag2: Myc; rag2:EGFP) transgenic zebrafish [14] , and intravenously injected these T-ALL cells into 2-day-old zebrafish embryos [15] . One day after injection, embryos bearing GFPlabeled T-ALL cells were treated with S63845, venetoclax or vehicle (dimethyl sulfoxide), each added to the fish water as single agents. After 4 days of treatment, the GFP-labeled T-ALL cells had proliferated and disseminated throughout the recipient embryos that were treated with vehicle, S63845, or venetoclax ( Fig. 2a, b) . To further investigate why the Mycdriven zebrafish T-ALL cells are insensitive to MCL1 inhibition as a single agent, we treated zebrafish embryos with S63845 and venetoclax, either as single agents or in combination. Then we analyzed lysates of whole embryos by western blotting, and we observed marked compensatory upregulation of both BCL-2 and MCL1 protein levels upon treatment with either drug ( Supplementary Figure 9 ). BCL-2 was not upregulated in response to S63845 in T-ALL cell lines treated in vitro, accounting for the apoptotic response of T-ALL cell lines but not zebrafish thymocytes in vivo to treatment with S63845 as a single agent. There are not sufficient cells in the zebrafish embryos to study only the thymocytes by western blotting, but at least at the whole embryo level, compensatory upregulation appears to explain resistance to treatment with each drug as single agent.
The major impact of S63845 and venetoclax was evident when they were administered together. At 10 μM S63845 plus 10 μM venetoclax, this combination greatly reduced the number of leukemic cells in the vast majority of embryos after 4 days of treatment ( Fig. 2a, b) . Importantly, the synergistic anti-T-ALL effects of S63845 plus venetoclax were documented in vivo at several different dosage levels by isobologram analysis (Fig. 2c) , indicating that MCL1 and BCL-2 inhibitors are synergistic at multiple dosage levels leading to T-ALL cell apoptosis in vivo with acceptable tolerance by normal cells.
To address the effects of treatment on survival of the transplanted embryos, we removed the drugs after treating the embryos with S63845 and venetoclax as single agents or combinations for a period of 4 days and then started feeding the embryos and observed them an additional 10 days ( Fig. 2d ). We found that treatment with the combination of S63845 and venetoclax significantly extended the overall survival of T-ALL bearing embryos, whereas single drug treatment with either drug had no impact survival. The treatments did not affect the viability of leukemia-free fish, excluding possibility that the fish treated with the combination died from toxicity of the treatment they received ( Supplementary Figure 10) . In addition, the fish treated with the combination exhibited growth of the GFP-labeled T-ALL cells after stopping the drugs and prior to their death. The last four fish were killed at day 13 with rapidly growing, disseminated GFP-positive T-ALL cells for humane reasons (Fig. 2d) .
In conclusion, our study demonstrates that the MCL1specific inhibitor S63845 actively kills human T-ALL cells as a single agent and acts synergistically with venetoclax to more potently induce apoptosis. These drugs were well tolerated in the zebrafish model when given alone and in combination. Interestingly, neither drug alone could effectively kill transplanted T-ALL cells growing in vivo, apparently owing to upregulation of MCL1 and BCL-2 levels in response to treatment with either drug. However, combined administration of S63845 and venetoclax led to profound synergistic activity against T-ALL in vitro and in vivo without appreciable toxicity even at doses that greatly reduced transplanted T-ALL cells in zebrafish embryos. Our results indicate that the newly developed MCL1-specific inhibitor S63845 warrants testing in clinical trials for relapse/refractory patients with T-ALL, both alone and in combination with venetoclax to simultaneously inhibit both MCL1 and BCL-2.
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Abstract
Multiple myeloma (MM) patients have an 11-fold increased risk of developing myeloid neoplasms compared to the general population; however, acute lymphoblastic leukemia (ALL) is rarely observed. Given that both MM and the majority of ALL are of B cell origin, this raises the question of whether ALL in patients with MM arises from the same clone. We report 13 cases of B-cell ALL following therapy for MM. The interval from MM diagnosis to ALL onset was 5.4 years (range 3.3-10). The median age at the time of ALL diagnosis was 60 years (range 43-67). MM therapy included immunomodulatory agents in all patients and autologous hematopoietic cell transplantation in 10 (77%) patients preceding ALL diagnosis. ALL genetics showed a normal karyotype, TP53 mutation/deletion, and monosomy 7 or 7q deletion in 5, 3, and 2 cases, respectively. Analysis of paired samples of MM and ALL using whole exome sequencing demonstrated that the malignancies arose from different clones. Thus, ALL as a second primary malignancy following MM is not clonally related but could potentially represent a therapy-related leukemia.
Second primary malignancies (SPM) remain a concern for patients with multiple myeloma (MM), especially as MM survival improves [1] . Large population-based studies suggest that the risk of an SPM is 26% higher in MM patients compared with the general population [2] . The etiology of these SPMs remains unclear, but theories implicate host, genetic, and MM treatment factors [1] .
The incidence of hematologic malignancies as an SPM in MM is 0.8-3.1% [3] [4] [5] . The majority of cases are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but acute lymphoblastic leukemia (ALL) has been occasionally reported [6] [7] [8] . The IFM2005 study and the CALGB100104 trial of lenalidomide maintenance following hematopoietic cell transplantation (HCT) reported three cases and one case of ALL, respectively [6, 7] . However, no details on their clonal origin were reported. Because both B-cell ALL and MM originate from abnormal post-germinal center B-cells, this fact raises the question of whether post-MM ALL represents a clonal dedifferentiation from a more indolent MM to an aggressive ALL, or a therapy-related leukemia triggered by the genotoxic effect of MM therapy [8, 9] . The transformation of mature B-cell lymphomas to ALL has been reported, with related clones in follicular lymphoma and unrelated clones in chronic lymphocytic leukemia [10, 11] . Other possibilities include the coincident development of two unrelated malignancies or the presence of a germline mutation predisposing the patient to several malignancies as noted in MM with other malignancies [12] .
Herein, we describe a single-institution series of ALL cases as SPM after MM, and we examine the clonal relationship between these two B-cell malignancies in a subset of cases to further explore their relationship.
We retrospectively reviewed all consecutive cases of adult ALL treated at City of Hope between 2000 and 2017, and we identified cases that had an antecedent MM diagnosis. This study was approved by the Institutional Review Board.
Six paired MM and ALL samples were obtained when available, and whole exome sequencing was performed to assess the clonal relationship between the two malignancies. Pre-autologous HCT mobilized stem cells and a bone marrow biopsy at remission were used as a surrogate for germline controls in 4 and 1 cases, respectively. These were the only available samples from the deceased subjects in the study. Genomic DNA was extracted with QIAamp DNA Micro Kit (Qiagen; Venlo, Netherlands) according to manufacturer instructions. The libraries were prepared with TruSeq Exome Library Prep Kit (Illumina; San Diego, CA, USA) and 100 ng of genomic DNA. Two or three libraries were pooled together and sequenced on Illumina HiSeq 4000 in highoutput mode with 100 paired-end reads to obtain a minimum coverage of 100× per sample. Sequencing data were analyzed using the pipelines of the Broad Institute of Harvard and MIT (Firehose, www.broadinstitute.org/ca ncer/cga), resulting in BAM files aligned to hg19 with calibrated quality scores [13] . We used MuTect within the Firehose framework to call somatic mutations in tumor aspirates [13] . We filtered out potential artefactual OxoG mutations as well as somatic single nucleotide variations (SSNVs) and indels present in a panel of normal samples. To estimate somatic copy number alteration, we used ReCapSeg (http://gatkforums.broadinstitute.org/ca tegories/recapseg-documentation), which calculated proportional coverage for each target region and then normalized each segment using the median proportional coverage in a panel of normal (PON) samples sequenced with the same capture technology. The sample was projected to a hyperplane defined by the PON, and the tumor copyratio was estimated. These copy-ratio profiles were segmented with CBS [14] . To estimate allelic copy number, germline heterozygous sites in the normal sample were called via GATK Haplotype Caller [15, 16] . Then, the contribution of each homologous chromosome was assessed via reference and alternate read counts at the germline heterozygous sites. Finally, we segmented the allele specific copy ratios using PSCBS [14] . Copy ratios and the force-called SSNVs and indels were used to estimate the sample purity, ploidy, and cancer cell fraction by ABSOLUTE [13] . To assess mutation clonality in matched samples, we used PHYLOGIC to perform clustering of ABSOLUTE CCFs, as previously described [13] .
Demographic, disease, and treatment characteristics were reported using descriptive statistics; median and range for continuous variables; and frequency and percent for categorical variables. Leukemia free survival (LFS) and overall survival (OS) were calculated from the date of ALL diagnosis using the Kaplan-Meier product-limit method. All analyses were performed using SAS version 9.4 (SAS Institute; Cary, NC, USA). Data were locked for analysis on 8 January 2018.
We identified 13 (1.3%) cases of ALL preceded by MM out of 1022 adults diagnosed with ALL; all had a B-cell phenotype. The median age at the time of ALL diagnosis was 60 years (range 43-67), and 62% were male. The median interval of latency from MM diagnosis to ALL diagnosis was 5.4 years (range 3.3-10.0), and the interval from the date of autologous HCT to ALL diagnosis was 4.3 years (range 2.7-6.0) ( Table 1) .
All patients received immunomodulatory drugs (IMiDs) as part of MM therapy before ALL onset, including six patients who were treated with lenalidomide and eight who were treated with thalidomide. Bortezomib was administered to 7 (54%) patients, chemotherapy (either standard dose or high dose [n = 10, 77%]) was given to 12 (92%) patients, and 3 (23%) patients had prior involved field radiation. Eleven patients received maintenance therapy, the majority with lenalidomide. Three (23%) patients had evidence of active MM at the time of ALL diagnosis.
With respect to ALL, the median white blood cell (WBC) count at the time of diagnosis was 2000/µL (range, 1.2k-29k). The hyperCVAD regimen was used as ALL initial induction in the majority of patients (n = 12, 92%), and 85% of all patients achieved complete remission (CR). Eight patients (62%) subsequently underwent allogeneic HCT. The median follow-up for all patients was 16.2 months (range 5.7-118.0). One-year event free survival and OS from the time of ALL diagnosis were both 77% (95% CI 44-92%).
Six paired MM and ALL DNA samples, as well as germline controls for all the cases but one, were available and underwent whole exome sequencing. One paired sample was excluded from downstream analysis because of lack of germline control. The mean coverage was 229X for all sequenced samples. We investigated the number and spectrum of somatic mutations and copy number alterations (CNA) in both neoplasms, and we did not identify any differences compared to publicly available datasets. Only three matched samples were further analyzed by PHYLOGIC due to low purity (<15%) for two of the matched samples. Phylogenetic analysis clearly indicated that ALL acute lymphoblastic leukemia, autoHCT autologous hematopoietic cell transplantation, IMID immunomodulatory drug, MM multiple myeloma, WBC white blood cell the two neoplasms are clonally unrelated, with clonal and subclonal mutations and CNAs unique to each malignancy ( Fig. 1) . Secondary hematologic malignancies are a known risk in patients with myeloma, and they mainly comprise cases of AML or MDS [17] . Originally, this finding was ascribed to the use of melphalan as a mainstay of MM therapy, and more recently, the use of lenalidomide, especially following autologous HCT [7] . On the other hand, ALL has rarely been noted.
Here, we have described a case series of ALL as an SPM after MM, encompassing the clinical and genetic features of this cohort. We have shown that all patients in this cohort were treated with IMiDs for their myeloma and the majority also underwent autologous HCT before ALL onset.
Both MM and the majority of ALL are B-cell malignancies, and their sequential development in the same patient may suggest an MM clonal dedifferentiation into a more aggressive form of B-cell malignancy, such as B-cell ALL. Nonetheless, our exome sequencing analysis of paired DNA samples from 6 cases of this cohort illustrated that the neoplasms were clonally unrelated, contradicting this hypothesis. On the other hand, therapy-related ALL has been described as a complication of exposure to cytotoxic therapies in the course of unrelated primary malignancies [8, 9] . Our ALL cohort was enriched with the TP53 mutation/deletion, as well as other genetic features observed frequently in therapy-related myeloid neoplasms, such as complex karyotype, monosomal karyotype and 7q deletion [18] . Therefore, we postulate that a subset of these cases could be therapy-related leukemia as the result of prior MM treatment, presenting as a B-cell ALL phenotype rather than the more frequently seen myeloid phenotype. Further evaluation of a larger cohort is required, and it would be of interest to expand this study to therapy-related acute myeloid leukemia and myelodysplastic syndrome. The responses are significantly different as measured by 2-way ANOVA, p = 0.031 (e) and p < 0.001 (f). g Western blot and quantitation of AKT phosphorylation in bone marrow cells harvested from mice transplanted with CALR-del52 expressing cells cultured in the presence of increasing doses of MK-2206 in vitro for 24 h. Bar graphs depict mean ± SD. n = 3 biological replicates. Grb2 is included as a loading control for the western blots recipients. Recipients developed splenomegaly, hepatomegaly and thrombocytosis by 14 weeks (Fig. 2a, f) , similar to previous reports [1, 4, 7] . Treatment of mice with MK-2206 20 weeks post-transplant led to significant reductions in spleen and liver weights (Fig. 2b) , as well as the total cell count in the spleen, but not the bone marrow (Fig. 2c) . The absence of a striking bone marrow effect could be the result of a greater dependence of hematopoiesis in the spleen in this animal model. We also observed decreases in the percentages of c-kit + and CD41 + cells and the number of megakaryocytes in the spleen, but not the bone marrow ( Fig. 2d-g) . Analysis of p-AKT levels revealed decreases in both total spleen and bone marrow cells (Fig. 2h ). This inhibition of AKT signaling failed to reduce the degree of thrombocytosis (Fig. 2i ), but it did prevent a further increase in the platelet count (Fig. 2j ). MK-2206 also had no significant effect on the hematocrit or other peripheral blood parameters ( Fig. 2i and data not shown). Given the modest effect of AKT inhibition as a single agent, we next combined MK-2206 with ruxolitinib. We observed synergy in inhibition of colony formation from murine hematopoietic progenitor cells expressing CALRdel52 (Supplementary Table 2 ). Of note, CFU-Mk assays revealed a much stronger synergy of MK-2206 with ruxolitinib than myeloid colonies. These results suggest that although MK-2206 showed modest activity as a single agent, combining it with ruxolitinib may enhance the anti-tumor effect of both drugs, especially against cells that are dependent upon MPL. Although ruxolitinib shows similar efficacy patients with any of the three driver mutations [8] , it has limited use in that most patients progress or become intolerant within 2-3 years [9] . Therefore, novel agents to enhance or follow ruxolitinib are needed. Here we demonstrate that AKT signaling is indeed increased in CALR mutant MPN patients and further reveal that AKT is a therapeutic target in this group of patients. With development of new PI3K/AKT inhibitors, inhibition of this pathway should be pursued in combination with ruxolitinib for the group of patients with CALR mutations. Dyskeratosis congenita (DC) caused by mutations in genes implicated in telomere biology is an inherited syndrome affecting multiple tissues. Clinical severity and the spectrum of symptoms are variable but classically patients present with significant hemato-immunological, odontological, mucosal, and dermatological disturbances [1] . This is due to defective telomere maintenance in rapidly renewing tissues, causing shortened telomeres and DC-like manifestations in the respective organ. Other common clinical features are hepatic, pulmonal, ophthalmologic, and neuropsychiatric health problems. DC also predisposes patients to cancer, especially hematological malignancies and squamous cell carcinomas of the head and neck [2] . Remarkably, the risk of myelodysplastic syndrome (MDS) is over 500-fold in comparison to healthy individuals [2] . Hence, early recognition of all patients with DC or other telomere biology disorder (TBD) is crucial.
One of the genes linked to DC is DKC1, located on chromosome X and encoding a highly conserved protein dyskerin. Dyskerin is an essential nucleolar protein, which maintains stability of the human telomerase RNA (TERC) by interacting with H/ACA consensus sequence in TERC. Pathogenic mutations in DKC1 result in a dysfunctional protein, leading to reduced levels of TERC, decreased telomerase activity, and premature telomere shortening in males [3] . Dyskerin has a role also in controlling ribosome biogenesis [3] . X-chromosome inactivation (XCI) silences transcription from one of the two X chromosomes in female cells to balance expression dosage between males and females. The inactivation process is sometimes incomplete in human tissues, thus up to one-third of X-chromosomal genes may be expressed from both the active and silenced X chromosomes [3] . There are few reports on females with DKC1 mutation [4] [5] [6] . Here, we report results of detailed molecular and clinical investigation of three symptomatic sisters aiming at enlightening X-linked TBD in females.
We recently identified two brothers with a novel DKC1 mutation c.1218_1219insCAG, p.(Asp406_Ser407insGln) resulting in short telomeres and manifestation of DC [6] . Three female siblings (mother and two aunts of the brothers) were studied at the Department of Hematology in Helsinki University Hospital Comprehensive Cancer Center in 2016-2017 amid hematologic consultation of the brothers. Clinical examination and sampling for extended routine analyses, as well as research laboratory analyses, were performed for all the females. Informed consents were obtained from participating individuals. This study was conducted in accordance with the principles of Helsinki Declaration and was approved by the Ethics Committee of Helsinki University Hospital (#206/13/03/03/2016). Detailed descriptions of the study subjects and analyses are presented in Fig. 1, Supplementary Table 1 , and in the Supplementary information.
All the females were confirmed to be heterozygous DKC1 mutation carriers by Sanger sequencing. In order to study X-inactivation in various tissues, we compared the DKC1 expression levels and distribution of wild type (WT) and mutant alleles in blood, buccal mucosa, tongue, and Epstein-Barr virus (EBV)-transformed lymphocytes using Sanger sequencing and droplet digital PCR (ddPCR). ddPCR is superior to traditional quantitative PCR as it is more sensitive and allows absolute quantitative measurement of RNA expression [7] (Fig. 2) . With ddPCR, the mutant allele burden in blood was 0% in the mother, 45% in aunt 1, and 5% in aunt 2. Also, buccal mucosa and tongue samples showed varying amounts of mutant DKC1 allele expression in all the females (Fig. 2) . Although we observed both mutant and WT alleles to be present, e.g., in blood samples, it is possible, or even likely, that signals come from different cells expressing either WT or mutant DKC1, and not both. The EBV-transformed lymphocytes showed extremely high overall DKC1 expression, >98% being WT DKC1 ( Supplementary Figure 1) . Dyskerin expression has been reported to be similar in EBV-transformed lymphoblastoid cells in mutation carrying females vs. controls [8] .
Here, we show that the extremely high DKC1 expression in transformed cells does not reflect the situation in naïve cells. This is not surprising as such, since dyskerin expression increases with malignant transformation [9] . Consequently, EBV-transformed lymphoblastoid cells should not be used in evaluation of telomere functionality.
The telomere lengths (TL) were measured in whole blood by a quantitative PCR-based method [10] . Two out of the three females (mother and the aunt 1) had shortened telomeres compared to age-matched controls (Supplementary Figure 2 ). The telomeres in the two brothers were previously shown to be very short (<5th percentile) and are depicted in the same figure for comparison. According to the literature, there is not a strict relationship between TL and severity of symptoms at an individual level [11] . Families have been reported where individuals display variable symptoms and differences in telomere lengths even though they carry the same mutation [12, 13] . Also, gene/ mutation-specific effect on TL is unclear. The brothers with extremely short TL had clear clinical mucocutaneous and immunological manifestations of DC. However, in the females, the correlation of TL with clinical presentation was less obvious and inquired more detailed investigation. The expression of DKC1 measured by ddPCR in blood correlated better with, e.g., anemia.
In DKC1-linked TBD, skewed X-inactivation has been thought to function especially well in hematopoietic tissues [6] and protect females from hematologic symptoms. In our study, both mutant and WT DKC1 are expressed in blood in two out of three females. They both have suffered from marginal macrocytic anemia for some years. Bone marrow biopsy examination in aunt 2 showed mild hypoplasia and explained for the findings in the blood picture. It is highly likely that also aunt 1 has corresponding findings in her bone marrow, although sampling has been postponed due to more urgent ophthalmologic procedures. Interestingly, and in accordance with previous findings in patients with DC, all the carrier females had elevated levels of hemoglobin F potentially suggesting for stress hematopoiesis and bone marrow failure syndrome. It has been speculated whether clonal hematopoiesis can precede myeloid malignancy in patients with DC. Thus, potential development of clonal hematopoiesis in the two aunts with anemia was investigated by a myeloid nextgeneration sequencing panel. Neither of the patients had any somatic mutations in genes involved in myeloid neoplasms, corresponding well to recent findings [14] . A long-term surveillance of genomic evolution in DC patients is still indicated aiming at early detection of MDS.
Regarding other clinical findings in our study patients, at least two of the three females had abnormal early graying of hair and nail atypia ( Supplementary Table 1 ). Also, subtle dermatologic features indicative of DC were present in both aunts ( Supplementary Figure 3) . However, they lacked the typical reticular pigmentation of the head and neck.
In summary, we demonstrate here that in rare diseases such as TBDs, careful clinical and molecular examination of one family can significantly increase our knowledge on disease features. Despite X-linked inheritance, two out of three females in this study fulfill the diagnostic criteria for DC-or DC-like syndrome [1] . In conjunction with widening the clinical spectrum of DKC1-linked TBD in women, we are also able to reveal the molecular roots of patients' symptoms. Whether the unique distribution pattern of mutant and WT DKC1 in distinct tissues arises by co- Expression levels and distribution of mutant (mut; blue) and wild type (WT; green) alleles in blood, buccal mucosa, and tongue detected with ddPCR duplex assay. Sanger sequencing chromatogram from buccal mucosa of aunt 1 exemplifies how this method is not suitable for absolute quantification. Insertion of three nucleotides in DNA sequence is marked with an arrow. Concentrations (copies/µl) of mut and WT cDNA copies reverse-transcribed from tissue sample RNA from all the females are shown (note different y-axis scales). The error bars represent Poisson 95% confidence intervals incidence or is a controlled biological phenomenon, remains to be investigated. DC is a multi-organ disease with high incidence of developing malignancies [2] . Since the health problems in female DKC1 mutation carriers may also be significant, the identification, registration, and careful follow-up of these individuals is called for.
